一区二区三区四区在线99精品,亚洲欧美日韩综合在线观看,日韩精品一区二区三区久久综合,久久青青草原亚洲,欧美一区二区三区在线观看尤物

Recently, ibuprofen and other antipyretic and analgesic drugs are out of stock, and the elderly in Xuhui District pension institutions have a more urgent need for such drugs! After learning about this situation, xuhonglei, chairman of Suzhou No.4 pharmaceutical factory, donated 500 boxes of dextroprofen capsules to Xuhui District, Shanghai on December 28, 2022 to support the cause of serving the elderly and caring for the elderly with practical actions. Subsequently, this batch of drugs will be distributed to welfare homes and other elderly care institutions through the elderly care centers, reasonably and orderly distributed to the elderly in need, and they will really be used on the blade.

Xuhonglei, a "post-80s" entrepreneur, graduated from the school of basic science and materials at Tsinghua University. He has been engaged in drug research and development for a long time. He is a domestic expert in anti infective drugs against coronavirus, African swine fever virus, Candida and other viruses and fungi. He is currently the chairman of Shanghai Chaorui group / Suzhou No.4 Pharmaceutical Factory Co., Ltd.

In 2022, xuhonglei was rated as "enlightening young talent". He led the drug development teams in Zhangjiang and Suzhou to complete the technical development of nearly 50 blockbuster drugs, and has implemented the production and operation of eight projects in Suzhou No.4 pharmaceutical, Sinopharm group and Inner Mongolia Grint, two of which are new crown therapeutic drugs, which have brought more than 2billion yuan of economic and social value to the country.

Since the outbreak of Xinguan, the fourth pharmaceutical factory in Suzhou has shouldered the burden of ensuring drug supply, and has now achieved an annual output of 10million boxes of dextroprofen capsules. This comprehensive pharmaceutical enterprise with a history of 70 years, specializing in the R & D and manufacturing of raw materials and preparations, has not only developed and produced dexibuprofen capsules that understand thermal analgesia, but also developed new crown specific drugs that can remove viruses. Xuhonglei said, "this drug is expected to be launched in 2023, which can effectively reduce the severe disease rate and meet the urgent needs of the people for the treatment of new crown drugs."